Evidence map›Paper›PMID 29234595›Full record

ArticleLeukemia research reports2017

Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature.

Arcari Annalisa, Bassi Simona, Pochintesta Lara, Trabacchi Elena, Moroni Carlo Filippo, Rossi Angela, Zanlari Luca, Vallisa Daniele

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Arcari AnnalisaHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Bassi SimonaHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Pochintesta LaraHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Trabacchi ElenaHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Moroni Carlo FilippoHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Rossi AngelaTransfusional Centre and Immunohematology, Immunogenetics Laboratory, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Zanlari LucaDepartment of Internal Medicine, Valdarda Hospital, via Roma 6, 29017 Fiorenzuola d'Arda, Piacenza, Italy.
Vallisa DanieleHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Guglielmo da Saliceto Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a "real life" situation.

Indexed as

Allogeneic hematopoietic stem cell transplantationB-cell receptor inhibitorsChronic lymphocytic leukemiaTP53 mutation

Identifiers

PMID29234595
PMCPMC5717301
OpenAlexW2768282552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.